about
Construction of a transcription map around the gene for ataxia telangiectasia: identification of at least four novel genesThe PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.The DNA double-strand break repair gene hMRE11 is mutated in individuals with an ataxia-telangiectasia-like disorderATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial.Telomere length predicts progression and overall survival in chronic lymphocytic leukemia: data from the UK LRF CLL4 trial.A regulatory role for NBS1 in strand-specific mutagenesis during somatic hypermutationThe role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia.Clonal diversity of Ig and T-cell receptor gene rearrangements in childhood B-precursor acute lymphoblastic leukaemia.PFI-1, a highly selective protein interaction inhibitor, targeting BET BromodomainsBET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia.Mutations revealed by sequencing the 5' half of the gene for ataxia telangiectasia.ATM mutations in sporadic lymphoid tumours.TLR-9 and IL-15 Synergy Promotes the In Vitro Clonal Expansion of Chronic Lymphocytic Leukemia B Cells.Mutations associated with variant phenotypes in ataxia-telangiectasiaA Hypomorphic PALB2 Allele Gives Rise to an Unusual Form of FA-N Associated with Lymphoid Tumour DevelopmentAssessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification.RIDDLE immunodeficiency syndrome is linked to defects in 53BP1-mediated DNA damage signalingT-cell number and subtype influence the disease course of primary chronic lymphocytic leukaemia xenografts in alymphoid mice.Absence of mutations in the ATM gene in breast cancer patients with severe responses to radiotherapyProduction and characterization of human proliferative T-cell clones specific for human papillomavirus type 1 E4 protein.Irradiation hybrids for human chromosome 11: characterization and use for generating region-specific markers in 11q14-q23.Molecular mechanisms involved in chemoresistance in paediatric acute lymphoblastic leukaemia.NK cell function is markedly impaired in patients with chronic lymphocytic leukaemia but is preserved in patients with small lymphocytic lymphoma.Down-regulation of ATM protein in HRS cells of nodular sclerosis Hodgkin's lymphoma in children occurs in the absence of ATM gene inactivation.Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses.The ATM tumour suppressor gene is down-regulated in EBV-associated nasopharyngeal carcinoma.USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status.USP7 is essential for maintaining Rad18 stability and DNA damage tolerance.The dual-acting chemotherapeutic agent Alchemix induces cell death independently of ATM and p53.ZAP-70 is highly expressed in most cases of childhood pre-B cell acute lymphoblastic leukemia.Residual ataxia telangiectasia mutated protein function in cells from ataxia telangiectasia patients, with 5762ins137 and 7271T-->G mutations, showing a less severe phenotype.Targeting the Ataxia Telangiectasia Mutated-null phenotype in chronic lymphocytic leukemia with pro-oxidants.Dynamic changes in clonal cytogenetic architecture during progression of chronic lymphocytic leukemia in patients and patient-derived murine xenografts.A physical map across chromosome 11q22-q23 containing the major locus for ataxia telangiectasia.Functional modules integrating essential cellular functions are predictive of the response of leukaemia cells to DNA damage.Pathogenic ATM mutations occur rarely in a subset of multiple myeloma patients.The impact of SF3B1 mutations in CLL on the DNA-damage response.A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival.Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers.
P50
Q24316396-3D2453D2-25F5-4DA9-8EF9-DB20281904B7Q27851580-3B5D4631-44C8-4352-8B75-BF5811D62E8CQ27853333-710E50AF-B339-494F-882E-4D5A84255F34Q28115238-9B95BBD1-F8C5-43A0-B686-66ECFA0EA16AQ30768193-CD48CE73-A2EC-46CB-8C47-3A2D9014AD94Q30986040-D2F0ED18-F5B3-4312-A084-91DB63D5F569Q33346216-BD020736-1BC3-4EAB-804F-DF0AA31B37B1Q33409459-B4B51039-3AB8-450F-8E7D-19CCDF287506Q33837936-B8D439AF-5D74-4E68-A403-F3B198D81148Q34338531-5691B2C3-C60E-4C14-B41E-D32BC4CEFD26Q34358853-D84F1E2C-BDE4-4287-8ADE-FFF2A5518433Q34395458-A9CB281A-BB76-42E1-B56D-9740C53DC50EQ34980360-6D1E8951-3F25-4D3A-B8BF-2E3D543F79D8Q35861964-C27FCC1C-8470-4D47-8FFE-C07C45224972Q35881927-EF63BBCA-4FE5-4EDC-AB94-76AA8EAEB209Q35962477-B363E65A-4C36-4A58-9808-D1D53019B17BQ36022313-7836F88E-06C3-43CA-845F-EBC6B96027E4Q36089253-3C230E95-92CD-4BF9-AF9B-CF94BA86A135Q36245171-C4D0A691-032B-406A-8F82-3CB19768B437Q36431591-1166A8F7-CC7F-4206-9A31-CFA7C37C68E7Q36645694-99064549-E9CE-4FF6-B8B2-07CED2D35690Q36777848-3954ABE4-FDB4-451F-A660-CFA5D459E491Q37249637-032B2715-68F6-4CAC-9AE6-FFF223E26D03Q37708827-0465C386-5DD1-45BE-A671-9D0EFDB874C4Q38298223-496DC168-686E-4969-8D6D-C37A5059F141Q38350727-D8F19D90-B474-4C1E-922E-0F21C6B617B3Q38357428-89DC0016-A40F-46BE-97E5-F6FFA95B946BQ38703821-3F35A103-5C9C-4B13-B46F-BF338E35442AQ38876635-F6CBA5F2-95F2-4F3B-8DBF-04B62E305D6DQ38965030-A01D27A3-CBBE-41C9-A9E1-8E0B8F5107BCQ40003594-71B65E20-2C7C-4A9B-B29B-17057BF7204CQ40802404-B6DEA003-BD51-45CA-8C20-C3A3653619A9Q40972934-03D9E983-60B4-4ED9-93A9-2777402559F5Q41280348-C7274283-0E5D-44F7-9338-64EAB1915650Q41464927-BC628B0C-6605-4C86-86A6-D0EE6E642101Q43905309-B1AF88FE-0E0C-4BA8-98F0-ADC8828BC162Q44176325-ABDAEBDE-7FC4-4A2D-B9E2-EEDDE73FD80DQ44290485-C6311091-B745-44A9-8E22-260F417010F7Q45251395-FDB2941E-3865-4C44-87FB-A1E5E75C91ADQ46503011-943E6816-6797-4271-99C4-B01068FA600B
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
T Stankovic
@ast
T Stankovic
@en
T Stankovic
@es
T Stankovic
@nl
type
label
T Stankovic
@ast
T Stankovic
@en
T Stankovic
@es
T Stankovic
@nl
prefLabel
T Stankovic
@ast
T Stankovic
@en
T Stankovic
@es
T Stankovic
@nl
P106
P31
P496
0000-0002-3780-274X